The DOI matches its Crossref record; 210 of the 211 references it cites were found in a registry or an index.
The tubular hypothesis of nephron filtration and diabetic kidney disease
Open accessAbstract
Kidney size and glomerular filtration rate (GFR) often increase with the onset of diabetes, and elevated GFR is a risk factor for the development of diabetic kidney disease. Hyperfiltration mainly occurs in response to signals passed from the tubule to the glomerulus: high levels of glucose in the glomerular filtrate drive increased reabsorption of glucose and sodium by the sodium-glucose cotransporters SGLT2 and SGLT1 in the proximal tubule. Passive reabsorption of chloride and water also increases. The overall capacity for proximal reabsorption is augmented by growth of the proximal tubule, which (alongside sodium-glucose cotransport) further limits urinary glucose loss. Hyperreabsorption of sodium and chloride induces tubuloglomerular feedback from the macula densa to increase GFR. In addition, sodium-glucose cotransport by SGLT1 on macula densa cells triggers the production of nitric oxide, which also contributes to glomerular hyperfiltration. Although hyperfiltration restores sodium and chloride excretion it imposes added physical stress on the filtration barrier and increases the oxygen demand to drive reabsorption. Tubular growth is associated with the development of a senescence-like molecular signature that sets the stage for inflammation and fibrosis. SGLT2 inhibitors attenuate the proximal reabsorption of sodium and glucose, normalize tubuloglomerular feedback signals and mitigate hyperfiltration. This tubule-centred model of diabetic kidney physiology predicts the salutary effect of SGLT2 inhibitors on hard renal outcomes, as shown in large-scale clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a paracrine manner, adenosine constricts the afferent arteriole through the adenosine 1 receptor, thereby decreasing glomerular perfusion and hyperfiltration, a central mechanism for progressive glomerular injury (21,22).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Chronic kidney disease: global dimension and perspectives
Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R., Wang, A. Y.-M., & Yang, C.-W. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60687-x · Cited by 4,383
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States
Saran, R., Robinson, B. M., Abbott, K. C., Agodoa, L. Y. C., Albertus, P., Ayanian, J. Z., Balkrishnan, R., Bragg‐Gresham, J. L., Cao, J., Chen, J. L. T., et al. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.12.004 · Cited by 2,192
Biology of Human Sodium Glucose Transporters
Wright, E. M., Loo, D. D. F., & Hirayama, B. A. (2011) · Physiological Reviews · doi:10.1152/physrev.00055.2009 · Cited by 1,430
Thomas, M. C., Brownlee, M., Suszták, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P. R., Groop, P., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,335
Research works printed but not linked: 1
- Fu, Y., Gerasimova, M., Mayoux, E., Masuda, T. & Vallon, V. SGLT2 inhibitor empagliflozin increases renal NHE3 phosphorylation in diabetic Akita mice: possible implications for the prevention of glomerular hyperfiltration. Diabetes 63, (supplement 1), A132 (2014).
Cited by
Sorted by citations
Items 301–400 of 467
Yokoyama, A., Suzuki, S., Okamoto, K., & Sugawara, A. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej22-0083 · Cited by 3
Liu, Y., Chen, Y., Yang, Q., Shen, D., Du, Z., & Zhang, G. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01988-8 · Cited by 3
Kidney Tubules — Scientific and Applied Value
Levitskaya, E. S., & Batiushin, M. M. (2022) · The Russian Archives of Internal Medicine · doi:10.20514/2226-6704-2022-12-6-405-421 · Cited by 3
Planting a path to kidney health: The vegetarian diet and diabetic nephropathy
Maqbool, M., Dar, M. A., & Ara, I. (2023) · Open Health · doi:10.1515/ohe-2023-0011 · Cited by 3
Nieczyporuk, M., Tyrna, P., Cader, T., Sikora, A., & Staneta, S. (2024) · Journal of Endocrinology and Metabolism · doi:10.14740/jem942 · Cited by 3
Tang, R., Kou, M., Li, X., Wang, X., Ma, H., Heianza, Y., & Qi, L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15874 · Cited by 3
Acetazolamide and Renal Hemodynamics
Ito, H., & Mori, T. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000731 · Cited by 3
Anatomophysiology of the Henle's Loop: Emphasis on the Thick Ascending Limb
Marcoux, A., Tremblay, L., Slimani, S., Fiola, M., Mac‐Way, F., Haydock, L., Garneau, A. P., & Isenring, P. (2021) · Comprehensive physiology · doi:10.1002/cphy.c210021 · Cited by 3
Yang, T., Hu, Y., Chen, S., Li, L., Cao, X., Yuan, J., Shu, F., Jiang, Z., Qian, S., Zhu, X., et al. (2023) · Cell Biology and Toxicology · doi:10.1007/s10565-023-09802-z · Cited by 3
Xiong, L. (., Garfinkel, A., Bennett, K. M., Baldelomar, E. J., Brown, L., Barrows, K. M., Vallon, V., Edwards, A., McDonough, A. A., Porat‐Shliom, N., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.12.675896 · Cited by 3
Self-citationAnatomophysiology of the Henle's Loop: Emphasis on the Thick Ascending Limb
Marcoux, A., Tremblay, L., Slimani, S., Fiola, M., Mac‐Way, F., Haydock, L., Garneau, A. P., & Isenring, P. (2022) · Comprehensive physiology · doi:10.1002/j.2040-4603.2022.tb00204.x · Cited by 2
Relationship among nephron number, cortical volume, and glomerular pressure in healthy kidney donors
Nobayashi, H., Kanzaki, G., Sasaki, T., Oba, R., Okabayashi, Y., Haruhara, K., Koike, K., Kobayashi, A., Yamamoto, I., Tsuboi, N., et al. (2025) · Physiological Reports · doi:10.14814/phy2.70462 · Cited by 2
Guo, X., Zhang, S., Sun, Q., Li, H., & Wang, L. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1627412 · Cited by 2
Assessment, molecular mechanisms and therapeutic targets for renal functional reserve
Fu, Z., & Deng, Y. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2526686 · Cited by 2
Lamba, J. K., Tandon, C., & Tandon, S. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10804-y · Cited by 3
Rodzoń-Norwicz, M., Potocka, N., Skrzypa, M., Zawlik, I., Milian-Ciesielska, K., Kogut, P., Gargasz, K., Maes, M. H. J., Sowa-Kućma, M., & Gala‐Błądzińska, A. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04592-4 · Cited by 2
EP3 promotes macrophage M1-polarization to play a critical role in diabetic renal injury
Chen, X., Ge, J., Yu, G., Fan, Y., Yang, J., Wu, B., Xu, Y., He, D., Zeng, Z., Peng, C., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117775 · Cited by 2
Apte, M. M., Kumthekar, G. V., & Tupe, R. S. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153479 · Cited by 2
Wu, X., Lu, H., Peng, Y., Xu, M., Qi, Y., Yi, Y., Song, Y., Wang, X., Liang, Y., Chen, T., et al. (2026) · ACS Nano · doi:10.1021/acsnano.5c17310 · Cited by 2
Cao, J., Dun, Z., Tian, D., Qiao, Z., & Wang, Y. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s580866 · Cited by 2
Mesenchymal Stem Cells Attenuate Diabetic Nephropathy by Suppressing the ERK-Ferroptosis-ROS Axis
Ma, S., Li, J., Wang, H., Wang, H., Peng, S., Han, Q., Bai, X., & Zhao, R. C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27115101 · Cited by 2
Habas, E., Rayani, A., Habas, A., Alarbi, K., Habas, A., Baghi, M., Habas, E., Errayes, E., Hamad, A., & Elzouki, A. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2688578 · Cited by 2
Chai, X.-J., Wei, G., Chen, W., Min, D.-Y., Wang, Y., & Guan, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1801502 · Cited by 2
Zhang, Z., Qu, Y., Wang, X., Ji, Y., Yao, J., Deng, W., Sun, G., Xu, H., Chen, X., & Hong, Q. (2026) · Research · doi:10.34133/research.1386 · Cited by 2
Physiology of Kidney Glucose Transport and Mechanisms of Kidney Protection by SGLT2 Inhibitors
Vallon, V. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_828 · Cited by 2
Self-citationAlsagaff, M. Y., Thaha, M., Pikir, B. S., Susilo, H., Wungu, C. D. K., Suryantoro, S. D., Haryati, M. R., Ramadhani, R., Agustin, E. D., Putra, M. R. A., et al. (2022) · F1000Research · doi:10.12688/f1000research.74985.1 · Cited by 2
SGLT2 Inhibitors Improve Cardiac Failure by Reducing Whole-Body Oxygen Demand: A Hypothesis
Onoue, T., & Kataoka, M. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01220-z · Cited by 2
Clinical Study of Haptoglobin and Type 2 Diabetes Nephropathy
张, 韵. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1351231 · Cited by 2
Bitencourt, A. D. S., Filho, R. L. V., Prestes, G. D. S., Uggioni, M. L. R., Marçal, F., Colonetti, T., & da Rosa, M. I. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03843-3 · Cited by 2
Николаевна, К. О., Korotkov, D. A., Sazhina, A. S., & Bogomolov, A. N. (2024) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2024-3014 · Cited by 3
SGLT2 inhibitors for the treatment of diabetes: a patent review (2019–23)
Baghel, R., Chhikara, N., Kumar, P., & Tamrakar, A. K. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2379929 · Cited by 3
Identification of key genes in diabetic nephropathy based on lipid metabolism
Yang, M., Wang, J., Meng, H., Xu, J., Xie, Y., & Kong, W. (2024) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2024.12695 · Cited by 2
Lin, Z., Gao, H.-Y., Shi, S., & Li, Y. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v16.i1.92711 · Cited by 3
Kaviya, R., Prasad, M. L. M., Pavithra, S., & Kapali, B. S. C. (2024) · International Conference on Data Intelligence and Cognitive Informatics (ICDICI) · doi:10.1109/icdici62993.2024.10810904 · Cited by 2
Gajić, S., Janković, S., Stojadinovic, M. M., Filić, K., Bontić, A., Pavlović, J., Mrđa, I., Petrović, K., Hadži-Tanović, L., Žunić, J., et al. (2025) · Metabolites · doi:10.3390/metabo15040271 · Cited by 2
Wu, X., Macklin, S., Zhang, Y., Thai, K., Nghiem, L., Ciano‐Oliveira, C. D., Coelho, N. R., Wang, H., Advani, S. L., Desjardins, J., et al. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70043 · Cited by 2
Alfaiz, A. S. (2025) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2025.100251 · Cited by 2
Bielopolski, D., Streja, E., Steinmetz, T., Rozen‐Zvi, B., & Kalantar‐Zadeh, K. (2022) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000847 · Cited by 2
Zhou, J., Jiang, S., Li, Z., & Li, W. (2023) · Diabetes Therapy · doi:10.1007/s13300-022-01361-6 · Cited by 3
Miñana, G., de la Espriella, R., Palau, P., Amiguet, M., Seller, J., Pinilla, J. M. G., Núñez, E., Górriz, J. L., Valle, A., Sanchís, J. M., et al. (2023) · Revista Española de Cardiología · doi:10.1016/j.recesp.2023.03.006 · Cited by 2
The Application of 4-Hexylresorcinol for Preventing Diabetic Complications
Kim, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-0637-2_8 · Cited by 2
SGLT2 inhibitors: diabetic kidney disease and beyond
Staruschenko, A., Bhalla, V., & Rangaswami, J. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00518.2020 · Cited by 2
SGLT-2 Inhibitors and Renal Outcomes in Non-Diabetic Patients: A Systematic Review
Sousa, M., Almeida, C., Marchão, N., Godinho, I., Lopes, J. A., & Gameiro, J. (2023) · Portuguese Journal of Nephrology & Hypertension · doi:10.32932/pjnh.2023.03.234 · Cited by 1
Knockdown of TMEM30A in renal tubular epithelial cells leads to reduced glucose absorption
Chen, S., Song, X., Xiao, Q., Wang, L., Zhu, X., Zou, Y., & Li, G. (2023) · BMC Nephrology · doi:10.1186/s12882-023-03299-8 · Cited by 1
[Research Progress in Stress-Induced Senescence of Renal Tubular Cells in Diabetic Nephropathy].
Yi, X., He, Y., & Chen, K. (2023) · PubMed Central · doi:10.12182/20231160107 · Cited by 1
Lessons learned from early-stage clinical trials for diabetic nephropathy
Rendell, M. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2326025 · Cited by 1
Horioka, K., Tanaka, H., Hayakawa, A., Takahashi, Y., Druid, H., Pakanen, L., & Porvari, K. (2025) · International Journal of Legal Medicine · doi:10.1007/s00414-025-03550-x · Cited by 1
Kim, J. S., Kim, W., Lee, H.-J., Jeong, K. H., Jeong, S. J., Jeong, M., Hwang, J., Hur, S., & Hwang, H. S. (2025) · Scientific Reports · doi:10.1038/s41598-025-07768-y · Cited by 2
Cleveland, K. H., Scholpa, N. E., & Schnellmann, R. G. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103698 · Cited by 1
WITHDRAWN: The Adverse Effects of Persistent Wound Stress on Patients with Type 2 Diabetes
Gao, C., Cai, X., Li, J., Jiang, J., Qian, B., Yang, R., & Xiong, F. (2025) · Burns · doi:10.1016/j.burns.2025.107765 · Cited by 1
RetractedWang, H. P., Lp, Y., Ao, D., Yang, K., Zou, S., Lin, Z., Liu, Q., & 文坤明 (2025) · Renal Failure · doi:10.1080/0886022x.2025.2605756 · Cited by 1
Korbut, A. I., Романов, В. В., & Klimontov, V. V. (2026) · Diabetes Mellitus · doi:10.14341/dm13350 · Cited by 1
Ahmad, Q. T., Haseeb, A., Ullah, W., Samad, M., & Afridi, A. (2026) · Cureus · doi:10.7759/cureus.103396 · Cited by 1
Özkan, M. A., Dayanan, R., Bulan, D. D., Özkan, H. D., Aktemur, G., Karabay, G., Çakır, B. T., Şeyhanlı, Z., Yıldırım, A. A., Akın, F., et al. (2026) · The European Research Journal · doi:10.18621/eurj.1854589 · Cited by 1
Nobayashi, H., Satoh, M., Hirose, T., Nakayama, S., Iwabe, Y., Hashimoto, H., Murakami, T., Okada, K., Mori, T., & Metoki, H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70625 · Cited by 1
Goodluck, H., Kanoo, S., Kim, Y. C., Lopez, N., Oe, Y., Currais, A. J. M., Maher, P. A., & Vallon, V. (2026) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00377.2025 · Cited by 1
Self-citationSalt and chronic kidney disease
Murray, J., Marsman, R. F. J., Engberink, R. O., & Vogt, L. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01076-y · Cited by 1
Zhang, H., Cai, Q., Gao, J., Wang, F., Zhang, L., Zhao, H., Ren, X., & Zhang, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1802447 · Cited by 2
Ya, S., Wang, W., & Li, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1785822 · Cited by 1
Ibrahim, N. A. S., Murugiah, H. R., Sarian, M. N., Rosli, N., Noor, M. M., Jantan, I., & Aizat, W. M. (2026) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-026-05753-3 · Cited by 1
Kim, Y., Jorge, A., Weber, B. N., & Costenbader, K. H. (2026) · Rheumatology · doi:10.1093/rheumatology/keag290 · Cited by 2
Oladeji, O., Semnen, B. P. K., Mugivhisa, L. L., & Olowoyo, J. O. (2026) · Measurement Food · doi:10.1016/j.meafoo.2026.100309 · Cited by 1
Witkowski, M., Przybyciński, J., Wojciuk, B., Czaja, W., Gołembiewska, N., & Gołembiewska, E. (2026) · Acta Biochimica Polonica · doi:10.3389/abp.2026.16436 · Cited by 1
Metabolic control by liver–kidney crosstalk and glucagon in health and disease
Vallon, V., & Albrechtsen, N. J. W. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01111-y · Cited by 1
Self-citationEffect of sodium-glucose cotransporter type 2 inhibitors on non-alcoholic fatty liver disease
Суплотова, Л. А., Kulmametova, D. S., Fedorova, A. I., Сергеевна, Д. Т., & Makarova, O. B. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-15-83-89 · Cited by 1
Das, F., Ghosh‐Choudhury, N., Maity, S., Kasinath, B. S., & Choudhury, G. G. (2023) · FEBS Letters · doi:10.1002/1873-3468.14599 · Cited by 1
Nakase, M., Ninomiya, K., Horiuchi, Y., Sekiguchi, M., Watanabe, Y., Setoguchi, N., Asami, M., Yahagi, K., Yuzawa, H., Komiyama, K., et al. (2023) · Internal Medicine · doi:10.2169/internalmedicine.1506-22 · Cited by 1
Atchou, K., Lawson-Evi, P., & Eklu‐Gadegbeku, K. (2023) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2023.101541 · Cited by 1
Habas, E. M., Habas, A. M., Elzouki, I., Alfitori, G. B., Arrayes, E., Rayani, A., Farfar, K., Habas, E., & Elzouki, A.-N. Y. (2024) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0044-1782673 · Cited by 1
Mani, S., Balasubramanian, A., Veluswami, K., Rao, S., & Aggarwal, S. (2024) · Cureus · doi:10.7759/cureus.63796 · Cited by 1
Hameed, S., Khan, M., & Ustrana, S. (2024) · Journal of Shalamar Medical & Dental College - JSHMDC · doi:10.53685/jshmdc.v5i1.139 · Cited by 1
Rong, G., Cai, Y., Weng, W., Chen, Y., Yu, X., Shao, M., Han, P., & Sun, H. (2022) · PubMed Central · Cited by 1
Lanceta, J. (2021) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/3769 · Cited by 1
SGLT-2 Inhibitors as Novel Treatments of Multiple Organ FibrosisPreprint
Hu, J.-P., Hui, S., Teng, J., & Liang, L. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4680858 · Cited by 1
Chen, D., Jiang, H., & Bao, J. (2024) · Research Square · doi:10.21203/rs.3.rs-4206752/v1 · Cited by 1
Heterozygous Hnf1a Mutation in Mice Reveals Multiple Pathogenic Mechanisms of HNF1A-MODYPreprint
Bonner, C., Acosta-Montalvo, A., Louvet, I., Saponaro, C., Moreno-Lopez, M., Thévenet, J., Delalleau, N., Gmyr, V., Giacobini, P., Espiard, S., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6369014/v1 · Cited by 1
Shafieizadegan, S., Yavari, P., Yazdi, M., Keikha, M., & Gholaminejad, A. (2025) · Research Square · doi:10.21203/rs.3.rs-7008420/v1 · Cited by 1
Wei, T., Huang, J., Li, Y., Yin, L., Tian, F., Wang, Q., & Zhou, E. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.11.664291 · Cited by 1
Aldosterone: Implications in Diabetic Nephropathy
Rehman, F. A., Razzak, Z. A., & Hussain, S. S. (2021) · National Journal of Health Sciences · doi:10.21089/njhs.53.0127
Focused Ultrasound Modulation of Hepatic Neural Plexus Restores Glucose Homeostasis in DiabetesPreprint
Cotero, V. E., Miwa, H., Hirschstein, Z., Qanud, K., Huerta, T. S., Tai, N., Ding, Y., Jimenez-Cowell, K., Tomaio, J. N., Song, W., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.16.440207
The role of glycoproteins in glomerular pathophysiology
Khramova, A. (2021) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Shimada, K., Kanasaki, K., Katô, M., Ogura, Y., Takagaki, Y., Monno, I., Hirai, T., Kitada, M., & Koya, D. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13760
Patent Highlights December 2021–January 2022
Mucke, H. A. (2022) · Pharmaceutical Patent Analyst · doi:10.4155/ppa-2022-0006
Aktuelles zu diagnostischen und prognostischen Biomarkern einer diabetischen Nephropathie
Herzog, C., Bose, K., Ganz, M. J., Mertens, P. R., & Scurt, F. G. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01004-9
A vese védelmében és azon is túl. A renoprotekció új lehetőségei
Balogh, D. B., Fekete, A., & Reusz, G. (2023) · Hypertonia és Nephrologia · doi:10.33668/hn.27.013
Yiqi Qingre Xiaozheng formula protects against diabetic nephropathy by restoring autophagy in mice
Sun, N., Yang, N., Zhou, J., He, Y., Wang, J., Liang, Y., Dai, R., Bai, J., & Chen, Z. (2023) · Journal of Traditional Chinese Medical Sciences · doi:10.1016/j.jtcms.2023.06.007
Die neuen Wunderdrogen - eine Einordnung aus nephrologischer Sicht
Weinmann‐Menke, J., & Kraus, D. (2023) · Info Diabetologie · doi:10.1007/s15034-023-4511-8
李, 燕. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.13102220
Tamizhan, S., Rajput, S., Rabari, K., Mamgain, G., & Naithani, M. (2023) · Acta Medica International · doi:10.4103/amit.amit_45_23
BÖBREK HASTALIKLARINDA NİTRİK OKSİT SENTAZ AKTİVİTESİ VE DÜZENLENME MEKANİZMALARI
ŞAHİN, A. C., Çavdar, C., & Çavdar, Z. (2024) · Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi · doi:10.18614/deutip.1231395
SGLT2 Inhibitors and Perioperative Euglycemic Diabetic Ketoacidosis
Mrazek, A. A. (2023) · Anaesthesia & Critical Care Medicine Journal · doi:10.23880/accmj-16000231
Yi, Z., Yang, B., Wan, F., Lu, J., Liu, D., Lin, L., Xu, Y., Cen, Z., Fan, M., Liu, W., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4798086
Nielsen, S. F., Duus, C. L., Buus, N. H., Bech, J. N., & Mose, F. H. (2024) · medRxiv · doi:10.1101/2024.05.28.24308079
Joseph, U. O., David, A. C., Marcus, I. C., Ndubuechi, I. A., & Precious, U. I. (2024) · International Journal of Research Publications · doi:10.47119/ijrp1001501620246737
Progress of SGLT2 inhibitors in the treatment of common immune-related nephropathies
Hu, G., Wu, Y., Chen, F., & Tang, J. (2024) · International Urology and Nephrology · doi:10.1007/s11255-024-04141-2
A Comprehensive Review of Emerging Therapies for Type 2 Diabetes and Their Cardiovascular Effects
G, A. J. A., Chitneni, E., Vidals, C. J. M., Modumudi, S., Hammad, S., Verma, A., Rajesh, R. Y., Khaliq, A., Adeyemi, O. T., Abid, F., et al. (2024) · Cureus · doi:10.7759/cureus.65707
Thomas, R. L., & Rifkin, D. E. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000458
Luo, H., Zang, Y., & Zhang, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00032-7
Aspectos fisiopatológicos relacionados à doença renal em indivíduos com diabetes mellitus
Sodré, G. R., Filho, O. C. R., de Carvalho, E. G., Yamanaka, F. R., Cavalcante, F. B., Lemos, I. D. P., de Lara, K. M. B., de Farias, M. H. B., Volkmer, M. C., & Campos, N. D. (2024) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e17823.2024
Coughlan, M. T., Trambas, I. A., Bowen, L., Thallas‐Bonke, V., Snelson, M., Sourris, K. C., Laskowski, A., Tauc, M., Rubera, I., Zheng, G., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5064706
Metadata
- Authors
- Vallon, V., & Thomson, S. C.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Vallon, Volker
- Venue
- Nature Reviews Nephrology
- Published
- 2020-03-09
- Volume
- 16
- Issue
- 6
- Pages
- 317-336
- ISSN
- 1745-8323 (ISSN-L)
- 1759-5061
- 1759-507X
- PMC
- PMC7242158
- OpenAlex
- W3009930262
- Cited by
- 465
- References
- 211
- Citations by year
- 2026: 80 · 2025: 75 · 2024: 79 · 2023: 70 · 2022: 79 · 2021: 55 · 2020: 24
- FWCI
- 9.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Reviews Nephrology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (1rf1ag061296-01a1)
- National Institute on Aging (RF1-AG061296)
- National Heart, Lung, and Blood Institute (R01HL142814)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK079337, R01DK106102, R01DK112042)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- diabetic nephropathy, glomerular hyperfiltration, tubuloglomerular feedback, SGLT2, SGLT1, proximal tubular reabsorption, macula densa, nitric oxide, renal fibrosis, SGLT2 inhibitors, glomerular filtration rate
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Chlorides, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Fibrosis, Glomerular Filtration Rate, Glucose, Humans, Hypertrophy, Inflammation, Kidney Glomerulus, Kidney Tubules, Nephrons, Nitric Oxide, Sodium, Cellular Senescence, Sodium-Glucose Transporter 1, Sodium-Glucose Transporter 2, Glomerular Filtration Barrier, Renal Reabsorption
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
